DIH Holdings US Stock Price, News & Analysis

DIH Holding US (NASDAQ:DHAI) has received a delisting notice from Nasdaq on September 2, 2025, after failing to meet the minimum market value requirement of $50 million for continued listing on the Nasdaq Global Market.

The company was initially notified of this deficiency on March 5, 2025, and was given a 180-day compliance period until September 1, 2025. DIH plans to request a hearing before the Nasdaq Hearing Panel, which will temporarily stay any delisting action. The Panel has the authority to grant DIH an extension of up to 180 days for market value compliance.

DIH Holding US (NASDAQ:DHAI) has received a deficiency notice from Nasdaq on August 26, 2025, due to failing to file its Q2 2025 Form 10-Q and FY 2025 Form 10-K. The company has until September 29, 2025 to submit a compliance plan to Nasdaq.

If Nasdaq accepts the plan, DIH could receive up to 180 days (until January 12, 2026) to regain compliance. The company is working with auditors to file the delinquent reports. Currently, there is no immediate impact on DHAI's Nasdaq listing or trading.

DIH Holding US (NASDAQ:DHAI), a global provider of advanced robotic rehabilitation devices, has appointed Scott R. Burell to its Board of Directors. Burell, currently CFO of AIVITA Biomedical, brings over two decades of healthcare finance experience and expertise in complex transactions.

As a seasoned executive, Burell has significant experience in public and private financing, corporate reorganizations, and M&A activities. He also serves on the Board of Microbot Medical (NASDAQ: MBOT) and previously led CombiMatrix Corporation through its acquisition by Invitae Corp. With his appointment, DIH's Board now consists of six members, including four independent directors.

DIH Holding US (NASDAQ:DHAI) has received a notice from Nasdaq on July 29, 2025, indicating non-compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Annual Report on Form 10-K for the period ended March 31, 2025.

The company has 60 calendar days to file the Annual Report or submit a compliance plan. If Nasdaq accepts the plan, DIH could receive up to 180 days from the original due date to regain compliance. While DIH is actively working with auditors to file the report, the notice currently has no immediate impact on the company's Nasdaq listing or stock trading.

DIH Holding US (NASDAQ:DHAI), a global provider of advanced robotic rehabilitation devices, has appointed Dennis Streppa to its Board of Directors and as Audit Committee Chair. Streppa brings significant healthcare industry experience, having served as a global Chief Operations Officer with expertise in both public and private healthcare companies.

His background includes driving M&A value at Cardinal Health, leading an $800M manufacturing P&L, and executing multi-million-dollar private equity deals. The appointment expands DIH's board to five members, with three being independent, strengthening the company's governance structure.

DIH (NASDAQ:DHAI), a global provider of advanced robotic rehabilitation devices, has appointed Professor Nick Ward, M.D. to its Scientific Advisory Board. Professor Ward, a distinguished expert in upper limb neurorehabilitation, serves as Professor of Clinical Neurology and Neurorehabilitation at University College London and the National Hospital for Neurology and Neurosurgery.

The DIH Scientific Advisory Board, now comprising nine members, advises the company on technical and scientific matters, clinical trends, product development, and research initiatives. Professor Ward brings expertise from leading a pioneering high-intensity Upper Limb Neurorehabilitation programme and researching neurobiological mechanisms in arm and hand function recovery.

DIH (NASDAQ:DHAI), a provider of advanced robotic rehabilitation devices, has designated Rehazentrum Valens as a DIH Center of Excellence. The Swiss rehabilitation center, established in 1970, specializes in neurological, musculoskeletal, and internal medicine rehabilitation.

Rehazentrum Valens utilizes DIH's comprehensive solution suite, including Erigo®Pro, Lokomat®Pro, Andago®, C-Mill VR+, and the complete Armeo® product family for various rehabilitation needs. The center has been implementing robotic-assisted rehabilitation for over 20 years, starting with one of the first Lokomat systems.

This partnership aims to showcase best practices in rehabilitation robotics and contribute to the development of advanced rehabilitation technologies, while demonstrating how DIH therapy solutions improve patient outcomes.

DIH (NASDAQ:DHAI) reported Q3 FY2025 financial results with revenue of $15.1 million, marking a 21% decline from the previous year. Device revenue fell 26% to $11.7 million, while service revenue grew 4% to $3.1 million. The company experienced significant revenue declines in EMEA (29%) and Americas (7%), primarily due to import restrictions related to the Russia-Ukraine conflict affecting Eastern European sales.

Gross profit decreased 30.4% while operating expenses increased, with SG&A rising 50.6% to $8.2 million. The company closed a public offering raising $4.6 million gross proceeds. Despite challenges, DIH reiterated its FY2025 revenue guidance of $60-67 million and announced new partnerships with Nobis Rehabilitation Partners and Zahrawi Group to expand its distribution network.

DIH (NASDAQ: DHAI) announced the expansion of its strategic partnership with Zahrawi Group to include Saudi Arabia, extending their collaboration that began in 2019. The partnership now covers four countries: UAE, Qatar, Bahrain, and Saudi Arabia.

The expanded collaboration aims to enhance the distribution of DIH's advanced robotic rehabilitation devices across these regions, leveraging Zahrawi Group's established presence in the Gulf Cooperation Council healthcare sector. DIH's technology incorporates visual stimulation for clinical research and functional rehabilitation in patients with walking impairments, reduced balance, and impaired arm and hand functions.

Dr. Patrick Bruno, DIH's Chief Market Officer, emphasized the partnership's focus on making advanced medical technologies more accessible to healthcare providers across the four countries. Abdulrahman Ramadan, Zahrawi Group's CEO, confirmed the alignment with their mission to provide innovative healthcare solutions.